INDIA COURT RULING AGAINST NOVARTIS IS DARK OMEN FOR BIG PHARMA $NVS $LLY $BMY $MRK $JNJ $PFE
It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected a plea by Swiss pharma giant Novartis that ends the seven-year legal battle to restrict Indian companies from copying blood cancer drug Glivec. Novartis had filed a plea with the Supreme Court after the Intellectual Property Appellate Board had rejected a patent claim for Glivec. Glivec is marketed as Gleevec in the United States. In 2001, Time magazine called it the magic bullet for cancer patients. The drug was originally developed as Imatinib using rational drug design after Philadelphia chromosome mutation was discovered. In India, Glivec